Cargando…

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

Castrate-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Several tyrosine kinases have been implicated in the development and growth of CRPC, as such targeting these kinases may offer an alternative therapeutic strategy. We established the combination of tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Archibald, Monica, Pritchard, Tara, Nehoff, Hayley, Rosengren, Rhonda J, Greish, Khaled, Taurin, Sebastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712974/ https://www.ncbi.nlm.nih.gov/pubmed/26811677 http://dx.doi.org/10.2147/IJN.S97286

Ejemplares similares

A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer
por: Taurin, Sebastien, et al.
Publicado: (2014)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect
por: Nehoff, Hayley, et al.
Publicado: (2014)

Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery – dual uptake through enterocytes and M-cells
por: Parayath, Neha N, et al.
Publicado: (2015)

Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer
por: Palmer, Hannah, et al.
Publicado: (2022)

Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer
por: Martey, Orleans, et al.
Publicado: (2017)

Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model
por: Parayath, Neha N, et al.
Publicado: (2016)

Theory and applications of nonparenteral nanomedicines
por: Kesharwani, Prashant, et al.
Publicado: (2020)

Oral Insulin Delivery Using Poly (Styrene Co-Maleic Acid) Micelles in a Diabetic Mouse Model
por: Bahman, Fatemah, et al.
Publicado: (2020)

Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy
por: Alkhalifa, Haifa, et al.
Publicado: (2021)

A multivariate statistical analysis of the effects of styrene maleic acid encapsulated RL71 in a xenograft model of triple negative breast cancer
por: Martey, Orleans N.K., et al.
Publicado: (2019)

Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Rana, Zohaib, et al.
Publicado: (2021)

Nilotinib-Associated Destructive Thyroiditis
por: Bakerywala, Suhalia, et al.
Publicado: (2015)

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
por: Nabhan, C, et al.
Publicado: (2012)

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics
por: Alhazzani, Khalid, et al.
Publicado: (2023)

Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
por: Zaborowska, Magdalena, et al.
Publicado: (2012)

Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease
por: Greish, Khaled, et al.
Publicado: (2017)

Nilotinib-Induced Keratosis Pilaris
por: Leong, Wai Mun Sean, et al.
Publicado: (2016)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
por: Na, Yoo Jin, et al.
Publicado: (2021)

Curcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer
por: Greish, Khaled, et al.
Publicado: (2018)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation
por: Roa-Chamorro, Ricardo, et al.
Publicado: (2023)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Nilotinib based pharmacophore models for BCRABL
por: Sabitha, Kesavan
Publicado: (2012)

Nilotinib – Differentiating the Hope from the Hype
por: Wyse, Richard K., et al.
Publicado: (2016)

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
por: Hochhaus, Andreas, et al.
Publicado: (2015)

Exploring the Mechanism and Suggesting Combination Therapies for HDAC Inhibitors in Androgen Receptor-Null Prostate Cancer Using Multivariate Statistical Analysis and Data Mining Techniques
por: Rana, Zohaib, et al.
Publicado: (2022)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

A case report of a rare complication of an iatrogenic ventricular septal defect secondary to radiofrequency ablation
por: Nehoff, Hayley L., et al.
Publicado: (2023)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Metastatic phenotype in CWR22 prostate cancer xenograft following castration
por: Seedhouse, Steven J., et al.
Publicado: (2015)

Effects of nilotinib on regulatory T cells: the dose matters
por: Fei, Fei, et al.
Publicado: (2010)

Nilotinib-induced Perforating Folliculitis: Two Cases
por: Saraswat, Neerja, et al.
Publicado: (2018)

Nilotinib: QTc prolongation: 2 case reports
Publicado: (2021)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
por: Wilson, Christabel, et al.
Publicado: (2017)

Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model
por: Wicklein, Daniel, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1ic8fn53gbr2c5jiu014kd6ghg